dsm-firmenich and Italian start-up Nous have entered a partnership to accelerate the global commercialisation of Koncentra, a caffeine-free botanical ingredient designed for energy, focus and mood applications.

Its industrial interest goes beyond positioning. The announcement highlights a low use level, solubility and limited impact on taste, colour and turbidity as formulation attributes for functional foods and beverages.

The collaboration also covers clinical-trial design, claims substantiation, regulatory positioning and market validation. It illustrates the pathway required to turn botanical screening into a scalable ingredient platform.

Functional statements currently come from the companies involved. A technical assessment still requires the identity and standardisation of the complex, dose, study design, population, comparator, results and conditions of use in each market.

Why it matters

The launch shows how an emerging ingredient must connect rationale, low use level, solubility, sensory impact, claims strategy and multi-market scalability.

Evidence limit

A company announcement dated 15 July, not an independent clinical publication. Composition, dose, completed studies and permissible claims require dossier-level review.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · dsm-firmenich ↗